Tyrosine Kinase Inhibitor Pharmacokinetics
From Proteopedia
(Difference between revisions)
| Line 4: | Line 4: | ||
|- | |- | ||
! colspan="1" align="center"| | ! colspan="1" align="center"| | ||
| - | ! colspan="2" align="center"| [[VEGFR]] & KIT | + | ! colspan="2" align="center"| [[VEGFR]] & KIT Inhibitors |
| - | ! colspan="3" align="center"| [[EGFR]] Inhibitor | + | ! colspan="3" align="center"| [[EGFR]] Inhibitors |
| + | ! colspan="1" align="center"| PDGFR Inhibitor | ||
|- | |- | ||
! Parameter | ! Parameter | ||
| Line 13: | Line 14: | ||
! [[Gefitinib]]<br/>(Iressa) | ! [[Gefitinib]]<br/>(Iressa) | ||
! [[Lapatinib]]<br/>(Tykerb) | ! [[Lapatinib]]<br/>(Tykerb) | ||
| + | ! [[Imatinib]]<br/>(Gleevec) | ||
|- | |- | ||
! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr) | ! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr) | ||
| Line 20: | Line 22: | ||
! 5.4 | ! 5.4 | ||
! 4 | ! 4 | ||
| + | ! [[Imatinib]]<br/>(Gleevec) | ||
|- | |- | ||
! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml) | ! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml) | ||
| Line 27: | Line 30: | ||
! 130 | ! 130 | ||
! 115 | ! 115 | ||
| + | ! [[Imatinib]]<br/>(Gleevec) | ||
|- | |- | ||
! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%) | ! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%) | ||
| Line 34: | Line 38: | ||
! 59 | ! 59 | ||
! Variable | ! Variable | ||
| + | ! [[Imatinib]]<br/>(Gleevec) | ||
|- | |- | ||
! [[Pharmacokinetics#Protein_Binding|Protein Binding]] (%) | ! [[Pharmacokinetics#Protein_Binding|Protein Binding]] (%) | ||
| Line 41: | Line 46: | ||
! 90 | ! 90 | ||
! 99 | ! 99 | ||
| + | ! [[Imatinib]]<br/>(Gleevec) | ||
|- | |- | ||
! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ||
| Line 48: | Line 54: | ||
! 26.9 | ! 26.9 | ||
! 9.6 | ! 9.6 | ||
| + | ! [[Imatinib]]<br/>(Gleevec) | ||
|- | |- | ||
! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ||
| Line 55: | Line 62: | ||
! 3850 | ! 3850 | ||
! 1429 | ! 1429 | ||
| + | ! [[Imatinib]]<br/>(Gleevec) | ||
|- | |- | ||
! Dosage (mg) | ! Dosage (mg) | ||
| Line 62: | Line 70: | ||
! 250 | ! 250 | ||
! 100 | ! 100 | ||
| + | ! [[Imatinib]]<br/>(Gleevec) | ||
|- | |- | ||
! Metabolism | ! Metabolism | ||
| Line 69: | Line 78: | ||
! Hepatic - (CYP3A4) | ! Hepatic - (CYP3A4) | ||
! Hepatic - (CYP3A4) | ! Hepatic - (CYP3A4) | ||
| + | ! [[Imatinib]]<br/>(Gleevec) | ||
|} | |} | ||
For references see: [[TYKI_References|References]] | For references see: [[TYKI_References|References]] | ||
Revision as of 15:47, 9 December 2010
| Tyrosine Kinase Inhibitor Pharmacokinetics | ||||||
|---|---|---|---|---|---|---|
| VEGFR & KIT Inhibitors | EGFR Inhibitors | PDGFR Inhibitor | ||||
| Parameter | Sunitinib (Sutent) | Sorafenib (Nexavar) | Erlotinib (Tarceva) | Gefitinib (Iressa) | Lapatinib (Tykerb) | Imatinib (Gleevec) |
| Tmax (hr) | 8 | 8.3 | 2.0 | 5.4 | 4 | Imatinib (Gleevec) |
| Cmax (ng/ml) | 24.6 | 460 | 69.6 | 130 | 115 | Imatinib (Gleevec) |
| Bioavailability (%) | Variable | 29-49 | 99 | 59 | Variable | Imatinib (Gleevec) |
| Protein Binding (%) | 95 | 99 | 93 | 90 | 99 | Imatinib (Gleevec) |
| T1/2 (hr) | 83 | 29 | 9.4 | 26.9 | 9.6 | Imatinib (Gleevec) |
| AUC (ng/ml/hr) | 1921 | 11040 | 20577 | 3850 | 1429 | Imatinib (Gleevec) |
| Dosage (mg) | 50 | 50 | 150 | 250 | 100 | Imatinib (Gleevec) |
| Metabolism | Hepatic (CYP3A4) | Hepatic (CYP3A4) | Hepatic - (CYP3A4) | Hepatic - (CYP3A4) | Hepatic - (CYP3A4) | Imatinib (Gleevec) |
For references see: References
